β-Adrenergic Receptor Blockade in Chronic Heart Failure

By M. Bristow. 2000

982 citations recorded by the source corpus.

Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism

View Paper: https://www.semanticscholar.org/paper/0a4e5d20bd9beab8ab26efd6b40837ac2c7141e1

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cardiology and Cardiovascular Medicine

1. R. J. Lefkowitz
2. K. Weeks
3. Bianca C. Bernardo
4. J. McMullen

In Endocrinology, Diabetes and Metabolism

1. K. Weeks
2. Bianca C. Bernardo
3. J. McMullen

Citations in the corpus

• Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. (2010, background): “However, prolonged adrenergic drive is detrimental and associated with desensitization and downregulation of β-ARs (Bristow, 2000).”
• Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets (2015, background): “However, chronic activation results in cardiac dysfunction and HF associated with desensitization and downregulation of β-ARs (Bristow 2000).”
• Molecular Mechanism of β-Arrestin-Biased Agonism at Seven-Transmembrane Receptors (2011, background): “Interestingly, chronic β-AR coupling to Gs is thought to be cardiotoxic (86, 87), whereas epidermal growth factor receptor transactivation has been reported to confer cardioprotection (85).”